83.68
前日終値:
$83.04
開ける:
$84.6
24時間の取引高:
5.60M
Relative Volume:
1.08
時価総額:
$48.18B
収益:
$6.30B
当期純損益:
$1.07B
株価収益率:
45.46
EPS:
1.8406
ネットキャッシュフロー:
$1.09B
1週間 パフォーマンス:
-1.03%
1か月 パフォーマンス:
-7.82%
6か月 パフォーマンス:
+2.22%
1年 パフォーマンス:
+6.61%
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EW
Edwards Lifesciences Corp
|
83.68 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
|
ABT
Abbott Laboratories
|
107.27 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
346.60 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
86.88 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.06 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-01 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | アップグレード | TD Cowen | Hold → Buy |
| 2025-12-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | アップグレード | Jefferies | Hold → Buy |
| 2025-10-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-10-07 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-04-24 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | アップグレード | Stifel | Hold → Buy |
| 2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | Truist | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
| 2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | ダウングレード | Stifel | Buy → Hold |
| 2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 開始されました | Mizuho | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 開始されました | Truist | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-27 | 繰り返されました | Citigroup | Buy |
| 2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Buy |
| 2022-01-27 | 繰り返されました | UBS | Neutral |
| 2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
| 2021-07-30 | 繰り返されました | Jefferies | Buy |
| 2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-30 | 繰り返されました | Stifel | Buy |
| 2021-07-30 | 繰り返されました | UBS | Neutral |
| 2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Underperform |
| 2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Outperform |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-09-23 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 開始されました | Deutsche Bank | Hold |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-16 | 開始されました | Barclays | Underweight |
| 2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
UBS initiates Edwards Lifesciences stock coverage with buy rating By Investing.com - Investing.com Canada
Form 4 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Bernard Zovighian sells $245,134 in shares - Investing.com
Form 144 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com South Africa
Form 144 Edwards Lifesciences Corp For: 27 July - Investing.com India
EW|Edwards Lifesciences Corp|Price:83.040|Chg%:+0.410 - TradingKey
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? - Yahoo Finance Singapore
Edwards Lifesciences (EW) insider Zovighian details recent $2.83M stock sale in Form 144 - Stock Titan
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences stock trades steady as TAVR growth supports margins - Ad-hoc-news.de
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium - Yahoo Finance
Edwards Lifesciences Corp (EW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edwards Lifesciences Corp (EW) Institutional Confidence - TradingKey
EW|Edwards Lifesciences Corp|Price:82.630|Chg%:-1.185 - TradingKey
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion - MedTech Dive
Why is Edwards Lifesciences stock rallying today? By Investing.com - Investing.com South Africa
Why is Edwards Lifesciences stock rallying today? - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Receives Upgrade from Leerink with New Price Target - GuruFocus
Edwards Lifesciences Reports Strong Q2 2026 Results With 13.6% Sales Growth, Raises Full-Year Guidance - Minichart
Piper Sandler raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Edwards lifts FY26 growth outlook following steady Q2 performance - Yahoo Finance
Edwards Lifesciences Corporatio (EW) Stock Forecasts - Yahoo Finance
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Life - Benzinga
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises - Yahoo Finance
EDWARDS LIFESCIENCES CORP : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $101 FROM $87 - Bitget
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating - marketscreener.com
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum - Investing.com
Edwards Lifesciences stock holds focus on margin and growth - AD HOC NEWS
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum By Investing.com - Investing.com Canada
Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 - marketscreener.com
EW|Edwards Lifesciences Corp|Price:83.800|Chg%:-0.570 - TradingKey
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo! Finance Canada
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements - GuruFocus
Edwards Lifesciences Announces Q2 2026 Financial Results Highlighting Market Leadership - Kalkine Media
Edwards Lifesciences (EW) Reports Strong Q2 2026 Sales Growth - GuruFocus
Edwards Lifesciences Q2 Earnings Call Highlights - Yahoo Finance
Edwards Lifesciences earnings up next: TAVR momentum in focus - Investing.com UK
Earnings call transcript: Edwards Lifesciences tops Q2 2026 estimates, lifts sales outlook - Investing.com
Edwards Lifesciences (EW) Reports Strong Q2 Earnings, Raises Rev - GuruFocus
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Edwards Lifesciences Jumps After Strong Q2 Growth and Higher 2026 Sales Outlook - Moomoo
Edwards Lifesciences jumps after strong Q2 growth and higher 2026 sales outlook - Quiver Quantitative
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth - WSJ
Is Edwards Lifesciences (EW) Undervalued After Q2 Earnings Beat? - GuruFocus
Edwards Lifesciences Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set - marketscreener.com
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):